China NMPA Product Recall - Implantable resynchronization therapy (RAPT) cardioverter defibrillator; Implantable resynchronization therapy (RAPT) cardioverter defibrillator; Implantable cardioverter defibrillator
China NMPA product recall for Implantable resynchronization therapy (RAPT) cardioverter defibrillator; Implantable resynchronization therapy (RAPT) cardioverter defibrillator; Implantable cardioverter defibrillator by Medtronic (Shanghai) Management Co., Ltd. published October 27, 2020. Recall level: Level 2 Recall. Medtronic (Shanghai) Management Co., Ltd. initiated a voluntary Class II recall on October 27, 2020,
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA product recall for Implantable resynchronization therapy (RAPT) cardioverter defibrillator; Implantable resynchronization therapy (RAPT) cardioverter defibrillator; Implantable cardioverter defibrillator by Medtronic (Shanghai) Management Co., Ltd. published October 27, 2020. Recall level: Level 2 Recall. Medtronic (Shanghai) Management Co., Ltd. initiated a voluntary Class II recall on October 27, 2020,
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox